Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Rhea-AI Summary
Minerva Neurosciences (NASDAQ: NERV) will host a virtual key opinion leader event on Feb 3, 2026 at 10:30 AM ET to discuss roluperidone and the unmet need of negative symptoms of schizophrenia. Speakers Gregory Strauss, PhD, and Brian Kirkpatrick, MD, MSPH, will join management to review patient burden, assessment challenges in the current regulatory environment, and how Minerva's planned confirmatory Phase 3 trial in 2026 uses a novel protocol aligned with FDA considerations to maximize the probability of success. A live Q&A will follow the presentations.
Positive
- None.
Negative
- None.
News Market Reaction – NERV
On the day this news was published, NERV gained 2.52%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.7% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $193M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NERV is up 1.79% while peers show mixed moves: LPCN +5.31%, but BIVI, NXTC, MTVA, and PRTG are down between 3.94% and 10.39%, suggesting a stock-specific driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Board/strategy update | Positive | +0.0% | Board appointment and consulting role to support roluperidone development. |
| Nov 05 | Earnings/financing update | Positive | +4.1% | Q3 2025 results plus details of $80M upfront financing and Phase 3 funding. |
| Oct 21 | Financing announcement | Positive | +141.0% | Private placement of up to $200M to fund Phase 3, NDA resubmission and launch prep. |
| Aug 14 | Earnings/clinical update | Negative | +25.4% | FDA requirement for new 52-week confirmatory study and strategic alternatives review. |
Recent news drew strong reactions to major financing and clinical-path updates, but governance and board changes saw muted price impact, indicating selective sensitivity to catalysts.
Over the last six months, Minerva highlighted financing and clinical plans for roluperidone. An October 2025-10-21 financing to fund a confirmatory Phase 3 trial saw a 140.98% move. Subsequent Q3 2025-11-05 results and financing details were followed by a 4.09% gain. A Q2 2025-08-14 update, including the need for a new 52-week trial and strategic review, coincided with a 25.35% move. Board expansion news on 2025-11-19 had a flat reaction. Today’s KOL event focus fits the ongoing Phase 3 narrative for roluperidone.
Market Pulse Summary
This announcement highlights Minerva’s effort to frame roluperidone’s role in treating negative symptoms of schizophrenia ahead of a confirmatory Phase 3 trial planned for 2026. The KOL event emphasizes unmet need, trial design aligned with an August 2024 FDA meeting, and the regulatory challenges in assessing negative symptoms. Investors may watch for details on protocol, endpoints, and how these align with prior financing earmarked for the Phase 3 program and potential NDA resubmission.
Key Terms
phase 3 clinical
schizophrenia medical
fda regulatory
clinical trials clinical
AI-generated analysis. Not financial advice.
BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, University of Arkansas for Medical Sciences). They will join the company management team to elaborate on the patient burden of the negative symptoms of schizophrenia, the challenges associated with assessing negative symptoms in the current regulatory environment and how the company’s upcoming Phase 3 trial of roluperidone is expected to meet those challenges.
To register, click here.
Current antipsychotics do not adequately treat the negative symptoms of schizophrenia despite decades of clinical trials and myriad FDA approvals. Recognizing there has never been a drug approved specifically for negative symptoms, FDA hosted a public meeting in August 2024 to establish the optimal approach in clinical trials. Minerva plans to start a confirmatory Phase 3 trial in 2026 utilizing a novel protocol, which is aligned with FDA considerations and designed to maximize the probability of a successful outcome.
A live question and answer session will follow the formal presentations.
About Gregory Strauss, PhD
Gregory Strauss, PhD, is the Franklin Professor of Psychology and Neuroscience at the University of Georgia where he directs the Clinical Affective Neuroscience Laboratory and Georgia Psychiatric Risk Evaluation Program. His research primarily examines the phenomenology, etiology, assessment, and treatment of negative symptoms in individuals diagnosed with schizophrenia and youth at clinical high-risk for psychosis. He has published over 275 widely cited papers. His research has been recognized with several awards (e.g., rising star award from the Schizophrenia International Research Society (SIRS), early career award from the National Academy of Neuropsychology (NAN), Wechsler early career award from the American Psychological Foundation) and supported by more than
About Brian W. Kirkpatrick, MD, MSPH
Brian W. Kirkpatrick, MD, MSPH, is a Peters Professor in the Department of Psychiatry at the University of Arkansas for Medical Sciences. Dr. Kirkpatrick is a nationally and internationally renowned expert on schizophrenia and related disorders, whose pioneering research has advanced many life-changing treatments. He graduated from the University of Texas Medical School at Houston. At the University of North Carolina Chapel Hill, he completed a psychiatry residency, the Robert Wood Johnson Clinical Scholar Program, a Master of Science in Public Health in epidemiology, and a fellowship in neuropharmacology. Dr. Kirkpatrick has focused on schizophrenia and related disorders. He co-chaired the National Institute of Mental Health (NIMH)-sponsored Consensus Development Conference on Negative Symptoms. He has been funded by NIMH, the National Institute of Diabetes and Digestive and Kidney Diseases, the Brain and Behavior Research Foundation, and the Scottish Rite Foundation. He was associate editor of Clinical Schizophrenia and Related Psychoses and has served on the editorial board of Schizophrenia Bulletin. He joined the University of Arkansas for Medical Sciences (UAMS) Department of Psychiatry in 2022 and in 2024 was awarded the John Emmett Peters Endowed Chair in Psychiatry.
About Negative Symptoms of Schizophrenia
Schizophrenia is a complex and disabling psychiatric disorder that affects millions of adults worldwide imposing a substantial health, social, and economic burden. Symptoms of schizophrenia are described in terms of positive, negative and cognitive symptoms.
Negative symptoms are extremely debilitating and ultimately prevent people from being able to live independently. Negative symptoms include blunted affect, alogia, avolition, anhedonia, and asociality. People suffering with impairing negative symptoms often require comprehensive care from healthcare systems and families and experience a reduced quality of life including significantly greater conceptual disorganization and psychosis, increased likelihood of hospitalization, poorer social functioning, pronounced social cognitive impairment, increased likelihood of unemployment or low-quality employment.
Approximately
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding the anticipated clinical benefits and market opportunities associated with roluperidone, including its potential to address clinical and regulatory challenges; and the expected timeline, design, and conduct of Minerva’s Phase 3 trial of roluperidone. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, Minerva’s future financial performance and position may not improve, resulting in difficulties in implementing Minerva’s business strategy, and plans and objectives for future operations; the expected sufficiency of Minerva’s existing cash resources and runway may not be accurate resulting in the need for additional financing sooner than anticipated or unexpected liquidity constraints; the internal and external costs required for Minerva’s ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Minerva’s plans or both; trials and studies may be delayed and may not have satisfactory outcomes, and earlier trials and studies may not be predictive of later trials and studies; the design and rate of enrollment for clinical trials, including the current design of the confirmatory Phase 3 trial evaluating roluperidone may not enable successful completion of the trial(s); the commercial opportunity for roluperidone in negative symptoms of Schizophrenia may be smaller than anticipated; Minerva may be unable to obtain and maintain regulatory approvals; Minerva may experience uncertainties inherent in the initiation and completion of clinical trials and clinical development; the need to align with collaborators or partners may hamper or delay development and regulatory efforts or increase costs; uncertainties of patent protection and litigation; general economic conditions; and other factors that are described under the caption “Risk Factors” in Minerva’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 25, 2025, as updated by its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Copies of reports filed with the SEC are posted on Minerva’s website at http://ir.minervaneurosciences.com/. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law.
Contacts:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
info@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
FAQ
When is Minerva Neurosciences (NERV) hosting the virtual KOL event on roluperidone?
Who are the featured speakers at Minerva's Feb 3, 2026 KOL event for NERV?
What will Minerva (NERV) discuss about roluperidone at the virtual event?
When does Minerva plan to start the confirmatory Phase 3 trial of roluperidone (NERV)?
Will there be an opportunity to ask questions during Minerva's NERV event on Feb 3, 2026?
